Roche Aktie News

Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholders in attendance, who represented 77.03% of the total 106,691,000 shares, approved the Annual Financial Statements and Consolidated Financial Statements for 2024, the Remuneration Report and the Sust...

Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.

Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

Basel, 17 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present new data at the Muscular Dystrophy Association (MDA) conference, 16-19 March, 2025, in Dallas, Texas, from its neuromuscular portfolio, including 12 oral and poster presentations. These data demonstrate the breadth of Roche's neuromuscular portfolio across spinal muscular atrophy (SMA) and Duchenne mu...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (VKTX 10.22%) and Roche Holdings (RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m.

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.

Roche partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. Roche gains the most advanced amylin analog that is available and strengthens its obesity pipeline as petrelintide can be used as monotherapy and in combination with Roche's existing obesity candidates. Zealand Pharma gains substantial upfront cash, significant potential milestones, and a...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as much as 29% shortly after the announcement, while Roche added 4.6%.